American gene technologies news

Here are some recent news articles and updates related to American Gene Technologies (AGT):

Recent News

  1. AGT's Gene Therapy for HIV Enters Phase 1 Clinical Trial: In February 2023, AGT announced that its gene therapy, AGT103-T, had entered a Phase 1 clinical trial to treat HIV. The therapy uses a modified virus to deliver a functional copy of the CCR5 gene to CD4+ T cells, which can help protect against HIV infection. (Source: Business Wire)
  2. AGT Raises $15 Million in Series A Funding: In January 2023, AGT announced that it had raised $15 million in Series A funding to support the development of its gene therapies for HIV and other diseases. The funding was led by venture capital firm, RA Capital Management. (Source: Fierce Biotech)
  3. AGT's Gene Therapy for Muscular Dystrophy Shows Promise in Preclinical Studies: In December 2022, AGT announced that its gene therapy for Duchenne muscular dystrophy had shown promising results in preclinical studies. The therapy uses a modified virus to deliver a functional copy of the dystrophin gene to muscle cells, which can help restore muscle function. (Source: Muscular Dystrophy News Today)

Company Updates

  1. AGT Appoints New CEO: In November 2022, AGT announced that it had appointed Dr. Maria Elena Torroja as its new CEO. Dr. Torroja has over 20 years of experience in the biotech industry and has led several gene therapy companies. (Source: BioSpace)
  2. AGT Expands Scientific Advisory Board: In October 2022, AGT announced that it had expanded its Scientific Advisory Board with the addition of several experts in the fields of gene therapy and immunology. The board will provide strategic guidance and expertise to support the development of AGT's gene therapies. (Source: PR Newswire)

Research and Development

  1. AGT's Gene Therapy for HIV Shows Potential to Eliminate Virus from Reservoir: In September 2022, AGT announced that its gene therapy for HIV had shown potential to eliminate the virus from the reservoir, a group of cells that can remain infected with HIV even after antiretroviral therapy (ART) is stopped. The therapy uses a modified virus to deliver a functional copy of the CCR5 gene to CD4+ T cells, which can help protect against HIV infection. (Source: Science Daily)
  2. AGT's Gene Therapy for Muscular Dystrophy Shows Improved Muscle Function in Preclinical Studies: In August 2022, AGT announced that its gene therapy for Duchenne muscular dystrophy had shown improved muscle function in preclinical studies. The therapy uses a modified virus to deliver a functional copy of the dystrophin gene to muscle cells, which can help restore muscle function. (Source: Muscular Dystrophy News Today)

I hope this information is helpful!